• iSpecimen posted a net loss of USD 2.28 million for the quarter ended March 31, 2026, widening 37%.
• Revenue fell 85% to USD 156,009, primarily due to a 61% drop in specimen count to 890.
• Operating loss widened 55% to USD 2.54 million as sales and marketing expense more than doubled to USD 1.54 million.
• Cash and cash equivalents slid 59% to USD 2.82 million, while management said conditions raise substantial doubt about its ability to continue as a going concern for one year after the report date.
• The company highlighted cost cuts from workforce reductions, a shift to higher-value suppliers following its supplier network refresh, and plans to reorganize commercial operations with an account-based sales approach and a new outbound sales team.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iSpecimen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058050), on May 18, 2026, and is solely responsible for the information contained therein.